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Delta-like ligand 4 (Dll4) is a Notch ligand that is
predominantly expressed in the endothelium. Evi-
dence from xenografts suggests that inhibiting Dll4
may overcome resistance to antivascular endothelial
growth factor therapy. The aims of this study were to
characterize the expression of Dll4 in breast cancer and
assess whether it is associated with inflammatorymark-
ers and prognosis. We examined 296 breast adenocar-
cinomas and 38 ductal carcinoma in situ tissues that
were represented in tissue microarrays. Additional
whole sections representing 10 breast adenocarcino-
mas, 10 normal breast tissues, and 16 angiosarcomas
were included. Immunohistochemistry was then per-
formed by using validated antibodies against Dll4,
CD68, CD14, Dendritic Cell-Specific Intercellular ad-
hesion molecule-3-Grabbing Non-integrin (DC-SIGN),
CD123, neutrophil elastase, CD31, and carbonic an-
hydrase 9. Dll4 was selectively expressed by intratu-
moral endothelial cells in 73% to 100% of breast ad-
enocarcinomas, 18% of in situ ductal carcinomas,
and all lactating breast cases, but not normal nonlac-
tating breast. High intensity of endothelial Dll4 ex-
pression was a statistically significant adverse prog-
nostic factor in univariate (P  0.002 and P  0.01)
and multivariate analyses (P  0.03 and P  0.04) of
overall survival and relapse-free survival, respec-
tively. Among the inflammatory markers, only CD68
and DC-SIGN were significant prognostic factors in
univariate (but not multivariate) analyses of overall
survival (P  0.01 and 0.002, respectively). In sum-
mary, Dll4 was expressed by endothelium associated
with breast cancer cells. In these retrospective subset
analyses, endothelial Dll4 expression was a statistically
significant multivariate prognostic factor. (Am J Pathol
2010, 176:2019–2028; DOI: 10.2353/ajpath.2010.090908)
The growth of tumors requires angiogenesis,1 which is
the consequence of increased expression of proangio-
genic factors (for example, vascular endothelial growth
factor A VEGF2,3). The expression of VEGF in cancer is
controlled by oncogenic signaling,4 hypoxia,5 and inflam-
matory cells.6 Although there is redundancy among proan-
giogenic factors in advanced cancer,7 many in vivo early
stage cancer models show VEGF dependence.8,9
This observation has been exploited clinically, where
the addition of an anti-VEGF antibody (bevacizumab) to
first line taxane-based chemotherapy in recurrent/meta-
static breast cancer was associated with prolongation of
progression free survival (from a median of 5.9 to 11.8
months, P  0.001).10 Nevertheless, there was no statisti-
cally significant overall survival benefit, and all patients in
this trial eventually progressed after 4 years.10 Furthermore,
a trial evaluating the addition of bevacizumab to capecitab-
ine in previously treated metastatic/advanced breast can-
cer demonstrated only a 10.7% improvement in response
rate and no survival benefit.11 To date, there are no vali-
dated clinical, radiological, or molecular biomarkers that
can predict the survival benefit afforded by bevaci-
zumab.12–15 Clinical data suggest that antiangiogenic
drugs are active in breast cancer,10,16 and it may be nec-
essary to identify biomarkers that predict their benefit.
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Additional agents that disrupt functional angiogenesis
have been developed to target tumors resistant to anti-
VEGF therapy.17,18 Recent studies have focused on Delta-
like ligand 4 (Dll4), a ligand for Notch receptors 1, 3, and
417–19 that is predominantly expressed by endothelial
cells.17–19 Transgenic mice in which Dll4 was replaced by a
reporter gene showed that Dll4 expression is restricted to
large arteries during development.20,21 Furthermore, Dll4
heterozygous knockout mice are reported to have defective
arterial development22 and venous malformations.22
Experimental systems17,23,24 have shown that Dll4-Notch
inhibition leads to increased sprouting and branching of
vessels in association with gradients of VEGF. Conversely,
VEGF blockade causes a reduction in Dll4 expression and
vessel sprouting.17,18,23–27 In addition, endothelial cells
transfected with Dll4 down-regulated VEGF receptors KDR
and neuropilin1 and showed reduced proliferative and migra-
tory responses to VEGF.28 The implication of this research is
that Dll4-Notch signaling regulates endothelial sprouting and
branching to form functional vascular beds, under the control
of VEGF and by autoregulation of VEGF signaling.23
Disruption of Dll4 signaling by overexpression or inhi-
bition of Dll4 may impair angiogenesis,17,18 and blockade
of Dll4-Notch signaling results in an increased density of
nonfunctional vasculature and is associated with a reduc-
tion in the growth of human tumor xenografts.17,18 In-
deed, certain xenografts that are resistant to anti-VEGF
therapy are reported to be sensitive to anti-Dll4,17,18,29
and combination treatment with anti-VEGF and anti-Dll4
has additive inhibitory effects on tumor growth.18 To-
gether these data provide a rationale to target Dll4 in
cancer and suggest that Dll4 may have a role in mediat-
ing resistance to anti-VEGF therapies.
Besides direct vascular effects, Fung et al30 showed
that Dll4-Notch signaling in macrophages stimulates a
proinflammatory response, which may be proangio-
genic.6 Moreover, Shojaei et al31,32 have reported that
bevacizumab resistance in certain preclinical in vivo can-
cer models is causally associated with tumor infiltration
by myeloid cells.
The characterization of Dll4 protein expression in hu-
man cancer is important for the rational design of clinical
trials to test the safety and activity of anti-Dll4 therapy.
Defining the pattern of Dll4 expression, in association with
markers of inflammation, may identify subgroups with dis-
tinct clinical behavior and responses to treatment. The aims
of this study were to characterize the in situ expression of
Dll4 in breast cancer, to assess the association between
Dll4 and established markers of inflammation (CD68, CD14,
neutrophil elastase, CD123, and Dendritic Cell-Specific Inter-
cellular adhesion molecule-3-Grabbing Non-integrin [DC-
SIGN]) and hypoxia (carbonic anhydrase 9 CA9), and to
determine the prognostic significance of these markers.
Materials and Methods
Patients and Tissue Samples
Formalin-fixed paraffin-embedded (FFPE) tissues were
obtained for 296 sequential patients with breast adeno-
carcinoma (surgery was performed between 1989 and
1998 at the John Radcliffe Hospital, Oxford, UK). Patients
were treated with a wide local excision and postoperative
radiotherapy or mastectomy with or without postoperative
radiotherapy. Postoperative chemotherapy (600 mg/m2
cyclophosphamide, 40 mg/m2 methotrexate, and 600
mg/m2 5-fluorouracil intravenously each on day 1 of a
21-day cycle 6) and hormonal therapy (tamoxifen 20
mg daily for 5 years) were offered according to local
protocols. Demographic, pathological, and treatment de-
tails are provided in Supplemental Table S1 (see http://
ajp.amjpathol.org). Sample size was determined by the
availability of tissue with clinicopathological data, survival
follow-up, and ethical approval for research. Two cases
had no survival data available. Follow-up data were cor-
rect as of January 2008, with a median follow-up time of
10 years, a median overall survival of 13.7 years, and a
median relapse-free survival of 13.8 years. Estrogen re-
ceptor (ER) content was determined by using an enzyme-
linked immunosorbent assay technique (Abbott Labora-
tories, Abbott Park, IL). Tumors were considered positive
when cytosolic ER levels were 10 fmol/mg of total cy-
tosolic protein. Receptor values were monitored by par-
ticipation in the European Organization for Research and
Treatment of Cancer (EORTC) quality control scheme. Hu-
man Epidermal growth factor Receptor 2 (HER2) status was
assessed with the HercepTest (Dako, Carpinteria, CA).
Tissue microarrays (TMAs) were assembled as de-
scribed previously33 with three replicate cores for each
tumor. Tissue from 38 patients with breast ductal carci-
noma in situ was also represented in TMAs for analysis.
An additional 10 breast adenocarcinomas, five normal
breast resections, five normal lactating breast tissues,
seven breast angiosarcomas, and nine nonbreast angiosar-
comas (five skin, one duodenal, one liver, one pleural, and
one vaginal) were also collected (John Radcliffe Hospital) to
investigate the expression of Dll4 in whole sections.
Approval was obtained for the use of all human tissue
from the local research ethics committee (C02.216). The
National Cancer Institute’s Reporting Recommendations
for Tumor Marker Prognostic Studies criteria were used in
the design, analysis, and interpretation of this research.34
In Situ Hybridization
A 727 base 35S-labeled (35S-UTP 800 Ci/mmol; PerkinElmer,
Waltham, MA) antisense riboprobe 100% homologous to
human DLL4 (position 2089 to 2815 of GenBank acces-
sion NM_019074.2) was generated by using T3 RNA
polymerase (Promega, Southampton, UK) from a linear-
ized blunt ended vector containing the above insert. Iso-
topic in situ hybridization, washes, and developing were
performed by using previously described methods.35 In
brief, FFPE tissue sections were deparaffinized in xylenes
and rehydrated through graded alcohols. Deproteination
was performed for 15 minutes at 37°C with 20 g/ml
proteinase K (Sigma-Aldrich, Gillingham, UK). Slides
were air-dried before hybridization overnight at 55°C.
Posthybridization, a series of increasingly stringent washes
were performed, and unhybridized probe was digested
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with 20 mg/ml RNase A (Sigma-Aldrich) for 60 minutes at
37°C. Slides were then dehydrated through a gradient of
alcohols, air-dried, and immersed in liquid film emulsion
(GE Health care, Chalfont St Giles, UK) for 14 days, before
they were developed and counterstained with H&E. In situ
hybridization for -actin on a serial section was used as a
positive control for mRNA integrity.
Immunohistochemistry
Immunohistochemistry for CD68 (clone KP1; Nuffield De-
partment of Clinical Laboratory Sciences, University of
Oxford, UK),36 CD14 (clone 223; Leica Microsystems,
Newcastle-on-Tyne, UK),37 neutrophil elastase (clone
NP57; Nuffield Department of Clinical Laboratory Scien-
ces),38 DC-SIGN (clone DC28; R and D Systems, Minne-
apolis, MN),39 CD31 (clone JC/70a; Dako),36 CA9 (clone
M75; a gift from Professor S. Pastorekova and Professor
J. Pastorek, Institute of Virology, Slovak Academy of Sci-
ences, Bratislava, Slovak Republic),40,41 CD123 (clone
7G3; BD Pharmingen, San Diego, CA),42 and Dll4 (clone
242; Regeneron, Tarrytown, NY)43 was performed either
manually or by using a Bond Max immunostaining ma-
chine (Leica) as per the manufacturer’s instructions with
controls for all experiments (tonsil and/or placenta for
inflammatory cell markers; renal cell carcinoma for CA9
and CD31; and renal cell carcinoma, normal kidney,
FFPE human umbilical vein endothelial cell pellets, and
FFPE U87 cell pellets transfected with empty vector or
recombinant human Dll443 for Dll4).
Immunohistochemistry for Dll4 was performed by us-
ing an anti-Dll4 monoclonal antibody (the variable re-
gions of this antibody are fully human, and the Fc-domain
is mouse; clone 242) that binds to the extracellular do-
main of human Dll4 (the epitope is in epidermal growth
factor-like domains 3 to 5) and generated in VelocIm-
mune mice (Regeneron). In brief, antigen retrieval was
performed in target retrieval solution (Dako) by using a
Decloaking Chamber (Biocare Medical, Concord, CA).
Sections were incubated for 16 hours at 4°C with the
primary antibody at 1 g/ml. Bound antibody was labeled
with Novolink polymer (Leica), visualized by using 2,3-
diaminobenzidine chromogen, and counterstained with
hematoxylin.
Cores were scored as positive for CA9 if membranous/
cytoplasmic expression was observed in 10% of epi-
thelial cells. Inflammatory markers were scored on a
semiquantitative scale, with negative cores scored 0,
cores with occasional positive inflammatory cells scored
1, cores with 10 to 30 labeled inflammatory cells scored
2, and cores with 30 labeled inflammatory cell infiltrate
scored 3. CD31 was scored 0 in tumor cores if there were
no vessels or 10 individual vessel profiles in a core, or
scored 1 if there were 10 profiles. Intensity of Dll4
expression by the endothelium was scored on a semi-
quantitative scale by two pathologists, with negative
cores scored 0, cores with weak expression scored 1,
and cores with moderate/strong expression scored 2.
The highest intensity score among replicate cores was
used as the score for each patient. All assays and anal-
yses were performed blind to the study endpoints.
Statistics
The 2 test was used to evaluate associations between
categorical variables. The false discovery rate controlling
procedure (threshold, P  0.05) was used to eliminate
spurious statistical associations as a result of multiple
testing.44 All survival analyses refer to overall survival
times, where death from any cause represents an event
or relapse-free survival, where first relapse or death from
any cause represents an event. The median and mean
survival times within each subgroup were estimated from
Kaplan-Meier curves. Patients were censored in survival
analyses according to the date last seen by a doctor. For
univariate and multivariate survival models, Cox regres-
sion analysis was used to identify prognostic factors. All
statistically significant prognostic factors in univariate
analyses were included in the multivariate model. All
statistical analyses were performed with SPSS Statistics
(version 16.0; SPSS, Chicago, IL). Two-sided P values
0.05 were considered statistically significant. Cases
with missing data were omitted from statistical analyses.
Results
Frequency and Pattern of Expression
Analyses of tumors from the 296 patients yielded infor-
mative data on 151 to 252 patients. Results were not
available for the remaining cases in certain assays be-
cause of exhaustion of TMAs with repeated sectioning
and loss of cores. However, all subsets analyzed were
representative of the total patient population (Supple-
mental Table S1, see http://ajp.amjpathol.org).
The monoclonal antibody (clone 242) that specifically
recognizes the extracellular domain of human Dll4 did not
stain U87 cells transfected with empty vector, but
showed membranous and cytoplasmic staining in U87
cells transfected with recombinant human Dll4 and un-
transfected human umbilical vein endothelial cells.43 Nor-
mal kidney did not express Dll4, but endothelial cells in
renal cell carcinoma showed endothelial expression of
Dll4, consistent with previous in situ hybridization re-
sults.43,45,46 CA9 and CD31 were expressed in tumor
cells adjacent to areas of necrosis and the endothelium of
the control renal cell carcinoma tissue, respectively.47,48
CD68 and CD14 were expressed predominantly by mac-
rophages present within the germinal centers of control
tonsil tissue.49,50 Neutrophil elastase was expressed ex-
clusively by neutrophil polymorphs present within control
inflamed tonsil tissue.38 DC-SIGN was expressed specif-
ically by myeloid dendritic cells in control tonsil and Hof-
bauer cells (specialized placental macrophages) in pla-
cental tissue.37 CD123 was expressed by plasmacytoid
dendritic cells in control tonsil tissue.51
In initial analyses of whole sections, in situ hybrid-
ization revealed selective expression of Dll4 by the
endothelial component of intra- and peritumoral ves-
sels, irrespective of their size and maturity (Supple-
mental Figure S1, see http://ajp.amjpathol.org). By im-
munohistochemistry, strongly positive cytoplasmic and
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membranous expression of Dll4 was observed in tumor
associated endothelium in 100% (10 of 10) of invasive
breast adenocarcinomas (Figure 1, A and B). No differ-
ence was observed in Dll4 expression by endothelium
within the tumor compared with endothelium at the inva-
sive edge. In the TMAs, 73% (170 of 232, of which 47
were score 2 and 123 were score 1) of the adenocarci-
nomas but only 18% (7 of 38, of which six were score 2,
and one was score 1) of in situ ductal carcinomas showed
endothelial expression of Dll4 (Figure 1, A–G). Differ-
ences between the TMAs and whole sections probably
reflect sampling bias, due to core selection. TMAs of
breast adenocarcinomas are generally constructed to
preferentially represent malignant epithelium (the cell
type of interest for most assays) and may, therefore,
under represent associated endothelium. Alternatively,
the small number of whole sections in this series (n  10)
may be insufficient to estimate accurately the proportion
of tumors with endothelial expression of Dll4. Neverthe-
less, scoring Dll4 in TMA cores is a valid means of as-
sessing microvessel density, equivalent to scoring endo-
thelial staining in three randomly selected high power
fields. Staining for CD31 in serial sections revealed that
the proportion of endothelium staining for Dll4 varied
considerably between tumors, from 0% to 100%. This did
not reflect vascular maturity or vessel size.
Nonlactating normal breast tissues (n  5 breast re-
duction tissues; Figure 1, C and D) were negative for Dll4
staining in all cell types. All cases of lactating non-neo-
plastic breast tissue (n  5) were positive for Dll4 in all
associated endothelium (irrespective of vessel maturity
or size), but no other cell types (Supplemental Figure
S2A, see http://ajp.amjpathol.org). Among the seven
breast angiosarcomas, three showed strong cytoplasmic
and membranous staining for Dll4 in all malignant endo-
thelial cells (Supplemental Figure S2B, see http://ajp.
amjpathol.org). One breast angiosarcoma showed Dll4
reactivity on 10% to 20% of malignant endothelial cells
and three breast angiosarcomas were negative for Dll4
expression. Of the malignant endothelial cells in the nine
nonbreast angiosarcomas, four were negative (one of five
skin and one of one vaginal), two were weakly positive (one
of one liver and one of five skin), and three were strongly
positive (one of one duodenal, one of one pleural, and one
Figure 1. Membranous/cytoplasmic Dll4 expression (brown) in endothelium adjacent to breast cancer (A) with matching CD31 expression (B) is shown.
Endothelium adjacent to normal breast does not express Dll4 by immunohistochemistry (C), but is identified by CD31 (D). Scale bar  100 m. Representative
examples of Dll4 scoring in endothelial cells (arrowheads), scored 0 (E), 1 (F), and 2 (G) are shown. Scale bar  25 m.
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of five skin) for Dll4 expression. Macrophages and dendritic
cells infiltrating breast adenocarcinomas showed membra-
nous/cytoplasmic immunoreactivity for Dll4 in approxi-
mately 10% of tumors (data not shown), consistent with
published research.30 Although not specifically scored,
20% to 60% of tumor cells in approximately 5% of breast
adenocarcinomas showed weak cytoplasmic/membranous
expression of Dll4 (data not shown), consistent with results
in colon cancer.43,52
Immunohistochemistry for inflammatory cell markers
selectively stained inflammatory cells with appropriate
morphology. Cells positive for CD68, a panmyeloid marker,
were observed infiltrating 73% (140 of 192) of breast
adenocarcinomas (Supplemental Figure S3A, see http://
ajp.amjpathol.org). The majority of these myeloid cells
were CD14 macrophages (Supplemental Figure S3B,
see http://ajp.amjpathol.org), observed in 46% (102 of
222) of breast adenocarcinomas. A small minority of
breast cancers showed infiltration by DC-SIGN positive
immature myeloid dendritic cells (6%, 13 of 228, Supple-
mental Figure S3C, see http://ajp.amjpathol.org) and/or
neutrophils (16%, 30 of 189; Supplemental Figure S3D,
see http://ajp.amjpathol.org). Plasmacytoid dendritic cells
(CD123) were only observed in one breast adenocarci-
noma (of 230 cases stained). In this instance CD123
cells were seen in a dense inflammatory cell infiltrate
some distance from the breast cancer cells (Supplemen-
tal Figure S3E, see http://ajp.amjpathol.org). Cytoplasmic/
membranous CA9 expression was seen in approximately
one third of breast adenocarcinomas (32%, 49 of 151,
Supplemental Figure S3F, see http://ajp.amjpathol.org).
All tumor cells adjacent to foci of necrosis were positive
for CA9, with a declining gradient of expression seen with
increasing distance from the necrotic core. Occasionally
CA9 expression was seen in tumor cells without adjacent
necrosis. This may reflect transient or early hypoxia that
has yet to progress to necrosis.
Associations Between Molecular and
Pathological Variables
Dll4 expression was positively associated with CD31 ex-
pression, reflecting microvessel density (Supplemental
Table S2, see http://ajp.amjpathol.org). However, the
presence of Dll4 positive endothelial cells was not asso-
ciated with hypoxia, as identified by CA9 expression, in
this series of breast adenocarcinomas. Dll4 endothelial
expression was associated with the presence of CD68
and CD14 inflammatory cells, but these associations
were not statistically significant after correction for multi-
ple testing. CD31 expression was positively associated
with infiltration by CD68, CD14, and neutrophil elastase
positive inflammatory cells. Expression of most inflamma-
tory markers was positively associated with each other,
suggesting that most inflammatory cell infiltrates contain
a mixture of myeloid cells.
Although many correlations were significant, after cor-
rection for multiple testing, few associations were ob-
served between molecular markers and clinicopatholog-
ical data. Lymph node involvement by tumor was
significantly associated with both CD68 (P  0.003) and
CD31 (P  0.01) expression (Table 1). ER status was
negatively associated with Dll4 (P  0.002), CD14 (P 
0.02), and neutrophil elastase (P  0.02). The use of
chemotherapy was significantly positively associated
with CD68 (P 0.01), neutrophil elastase (P 0.01), and
CA9 (P  0.001).
Survival
In univariate analyses of overall survival, age 50 years,
tumor size 2 cm, lymph node involvement, Dll4 expres-
sion (score 2 vs. 0 or score 2 vs. 1), CD68 expression
(score 2 vs. 0), DC-SIGN expression (score 1 or 2 vs. 0),
and CD31 expression were all adverse prognostic factors
(Table 2). In a Cox regression multivariate survival model
(Table 3) that included all significant adverse prognostic
factors from univariate analyses, only age 50 years,
lymph node involvement, and Dll4 expression were sig-
nificantly associated with overall survival (P  0.004,
0.01, and 0.03, respectively). These variables retain their
significance when chemotherapy, radiotherapy, and hor-
monal therapy are included in the model (P  0.015,
0.006, and 0.04, respectively).
When Kaplan-Meier curves of overall survival were
plotted for patients subgrouped according to Dll4 ex-
pression, overlapping curves were seen for patients scor-
ing 0 or 1 (Figure 2A). However, patients scoring 2 per-
formed significantly worse, with a mean overall survival of
7.4 years (95% confidence interval, 5.7 to 9.0), compared
with 11.7 years (95% confidence interval, 10.6 to 12.8) for
score 1 and 11.4 years (95% confidence interval, 10.1 to
Table 1. Statistical Significance of Associations between Molecular and Categorical Clinical Variables
Variable Age Grade Size
Nodal
status ER HER2 Chemotherapy Radiotherapy
Hormonal
therapy
Dll4 2.7 (0.26) 10.5 (0.03*) 2.7 (0.26) 0.2 (0.90) 12.6 (0.002†) 2.3 (0.32) 2.1 (0.34) 4.0 (0.13) 0.7 (0.71)
CD68 0.4 (0.82) 7.64 (0.11) 5.1 (0.08) 11.9 (0.003) 1.7 (0.44) 2.9 (0.23) 8.9 (0.01) 0.9 (0.64) 2.9 (0.23)
CD14 0.50 (0.92) 9.39 (0.15) 0.6 (0.90) 3.5 (0.32) 10.5 (0.02†) 3.7 (0.30) 5.44 (0.14) 2.28 (0.52) 1.60 (0.66)
Neutrophil
elastase
6.8 (0.03*) 11.3 (0.02*) 1.2 (0.54) 5.9 (0.05) 7.5 (0.02†) 0.6 (0.75) 9.0 (0.01) 1.2 (0.56) 5.4 (0.07)
DC-SIGN 2.3 (0.32) 6.6 (0.16) 2.0 (0.37) 0.7 (0.71) 0.3 (0.86) 0.85 (0.65) 0.4 (0.80) 6.7 (0.04*) 0.3 (0.86)
CA9 4.99 (0.17) 12.9 (0.05*) 5.2 (0.16) 3.5 (0.32) 24.9 (0.0001†) 0.74 (0.87) 17.4 (0.001) 3.1 (0.38) 1.2 (0.75)
CD31 0.1 (0.83) 5.1 (0.08) 0.3 (0.6) 6.2 (0.01) 3.8 (0.05) 1.4 (0.23) 3.0 (0.08) 1.4 (0.24) 1.6 (0.20)
Values presented as 2 (P).
*These P values are not significant following correction for multiple testing by the Benjamini and Hochberg false discovery rate controlling
procedure with a cut-off  0.05. All associations are positive unless marked as †negative association.
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12.8) for score 0. (Note median survival times are not
provided because they were not reached for score 0 or
score 1 subgroups.) Stratifying these data by tumor size
or nodal involvement yielded similar results (data not
shown). In addition, expression of Dll4 was a statistically
significant variable in univariate (P  0.01) and multivar-
iate (P  0.04) analyses of relapse-free survival (Figure
2B, Supplemental Tables S3 and S4, see http://ajp.
Table 2. Univariate Analysis of Overall Survival
Variable n Events Hazard ratio 95% confidence interval P*
Total 291 133
Dll4
0 62 27 1.00
1 123 48 0.90 0.56–1.44 0.66
2 47 32 2.29 1.37–3.82 0.002
CD68
0 52 19 1.00
1 77 32 1.19 0.68–2.10 0.55
2 63 39 2.00 1.16–3.47 0.01
CD14
0 120 52 1.00
1 49 24 1.16 0.72–1.89 0.55
2 39 16 0.90 0.52–1.58 0.72
3 14 8 1.61 0.77–3.40 0.21
DC-SIGN
0 215 91 1.00
1, 2 13 11 2.75 1.47–5.16 0.002
Neutrophil elastase
0 159 75 1.00
1 19 8 1.01 0.49–2.10 0.97
2 11 6 1.18 0.51–2.70 0.70
CA9
0 102 43 1.00
1 25 9 0.88 0.43–1.81 0.73
2 11 6 1.65 0.70–3.87 0.26
3 13 6 1.26 0.54–2.98 0.59
CD31
0 150 61 1.00
1 102 56 1.50 1.05–2.16 0.028
Age, yr
50 80 20 1.00
50 211 113 2.74 1.70–4.41 0.0001
Size, cm
2 123 45 1.00
2 167 87 1.73 1.21–2.49 0.003
Lymph nodes
Uninvolved 167 57 1.00
Involved 119 73 2.43 1.72–3.44 0.0001
Grade
1 28 10 1.00
2 129 60 1.26 0.65–2.47 0.50
3 94 47 1.52 0.77–3.01 0.23
Histology
Ductal 236 109 1.00
Lobular 32 14 0.89 0.51–1.57 0.70
Mixed 14 7 1.13 0.52–2.42 0.76
Other 9 3 0.55 0.17–1.72 0.30
ER
Negative 65 33 1.00
Positive 213 94 0.76 0.51–1.13 0.17
HER2
Negative 226 101 1.00
Positive 22 11 1.23 0.66–2.30 0.51
Radiotherapy
No 46 27 1.00
Yes 245 106 0.67 0.44–1.02 0.06
Chemotherapy
No 228 104 1.00
Yes 63 29 0.93 0.62–1.41 0.74
Hormonal therapy
No 83 34 1.00
Yes 208 99 0.72 0.48–1.07 0.10
*Cox regression analysis.
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amjpathol.org). Patients scoring 2 performed significantly
worse, with a mean relapse-free survival of 7.1 years
(95% confidence interval, 5.3 to 8.9), compared with 11.1
years (95% confidence interval, 9.9 to 12.2) for score 1
and 10.8 years (95% confidence interval, 9.3 to 12.3) for
score 0.
Discussion
The addition of an anti-VEGF therapy (bevacizumab) to
first-line taxane chemotherapy extends progression-
free survival in breast cancer, yet tumors eventually
progress.10 Moreover, the addition of bevacizumab to
chemotherapy has yet to demonstrate a benefit in overall
survival in human breast cancer.10 Biomarkers are cur-
rently sought to identify bevacizumab resistance and
targets for second-generation antiangiogenic drugs. Dll4
is a Notch ligand that is selectively expressed by endo-
thelium53 and is regulated by VEGF and hypoxia.46 Re-
cent data suggest that spatial regulation of Dll4 signaling
is involved in forming a functional vascular bed during
tumor angiogenesis,17,18 and manipulating Dll4-Notch
signaling may inhibit tumor growth.17,18 Furthermore,
there is growing evidence from model systems that Dll4
expression may define a subset of tumors that are resis-
tant to anti-VEGF therapies,28,29 and inhibition of Dll4 may
overcome bevacizumab resistance.28,29 If validated in
human cancer patients, these preclinical findings sug-
gest that Dll4 expression may have potential implications
for the use of bevacizumab in breast cancer. Indeed
characterizing Dll4 expression may better inform appro-
priate indications for the use of an anti-Dll4 antibody
(Regeneron), which has recently entered phase I clinical
trials. This is the first study to perform a detailed evalua-
tion of Dll4 expression in breast cancer and to relate Dll4
expression to other known histological and prognostic
markers.
Dll4 expression was observed in the cytoplasm and
membrane of the endothelium adjacent to invasive breast
cancer and the malignant endothelium of angiosarco-
mas, but not nonlactating normal breast tissue. This is
consistent with data from xenografts17 and in situ hybrid-
ization data for Dll4 in bladder cancer45 and renal cell
carcinoma.46,53 The lack of expression of Dll4 in the
endothelial cells of normal nonlactating breast tissue is in
keeping with the lack of VEGF expression and absence
of hypoxia in nonlactating breast.54 Lactating breast
showed high levels of Dll4 positive vascular density, com-
parable with breast cancer, but lower than normal breast
lobules. This is suggestive of physiological angiogenesis
Table 3. Multivariate Analysis of Overall Survival (n  156 with 71 events)
Variable Hazard ratio 95% confidence interval Association with shorter survival P*
Age 3.00 1.41–6.39 50 yr 0.004
Size 1.55 0.88–2.72 0.13
Nodal status 1.87 1.15–3.04 Involved 0.01
Dll4 1.55 1.05–2.29 High expression 0.03
CD68 1.17 0.80–1.70 0.42
DC-SIGN 1.33 0.83–2.15 0.24
CD31 1.34 0.79–2.28 0.27
*Cox regression analysis.
Figure 2. Kaplan-Meier overall survival (A) and relapse-free survival (B) curves for breast cancer patients subgrouped according to Dll4 expression is shown.
Overall survival, Cox regression: score 2 vs. score 0; hazard ratio: 2.29 (95% confidence interval, 1.37 to 3.82), P  0.002; score 2 vs. score 1, hazard ratio: 2.54
(95% confidence interval, 1.62 to 3.98), P  0.00005. Relapse-free survival, Cox regression: score 2 vs. score 0; hazard ratio: 2.03 (95% confidence interval, 1.19
to 3.47), P  0.01; score 2 vs. score 1, hazard ratio: 2.09 (95% confidence interval, 1.30 to 3.36), P  0.002.
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in lactating breast, driven by VEGF expression in lactat-
ing glandular epithelium.55 These data suggest that strat-
egies targeting Dll4-Notch signaling may selectively af-
fect the endothelium associated with breast cancer and
angiosarcomas, but not endothelium associated with nor-
mal breast tissue. Although the expression of Dll4 by
endothelium within lactating breast tissue may have im-
plications for the use of anti-Dll4 agents in pregnant
women, such women are usually excluded from clinical
trials. The heterogeneity in expression of Dll4 in angiosar-
comas is of interest because this tumor type could be
considered for therapies targeting Dll4. However, the num-
bers of cases in this series are too small to derive firm
conclusions. It also demonstrates the need to select pa-
tients appropriately if new therapies are being developed.
The pathology studies showed several associations
between the pathways. ER status was negatively associ-
ated with Dll4, CD14, and neutrophil elastase. This is
likely to be due to differing biology of ER/ cancers, with
a more hypoxic and proinflammatory phenotype in ER
cancers. The use of chemotherapy was significantly pos-
itively associated with CD68, neutrophil elastase, and
CA9. This reflects the strategy of treating more aggres-
sive cancers. For example, infiltration by CD68 myeloid
cells was associated with nodal metastasis, adverse
pathological stage and, therefore, an increased likeli-
hood of receiving adjuvant chemotherapy. Similarly, CA9
and neutrophil elastase were associated with high-grade
ER cancers, which are more likely to receive adjuvant
chemotherapy. CD31 expression was positively associ-
ated with infiltration by CD68, CD14, and neutrophil elas-
tase positive cells. This suggests that inflammatory cells
secrete proangiogenic factors and/or that tumors with a
high vascular density provide more opportunities for in-
flammatory cells to infiltrate the stroma.
Dll4 was a statistically significant prognostic factor in
multivariate analyses that included established clinico-
pathological prognostic variables, treatment effects, and
a well described panendothelial marker of microvessel
density (CD31). One possible explanation for the adverse
prognostic effect of Dll4 in breast cancer is that Dll4
expression is mechanistically associated with functional
vascular beds,29 unlike CD31. Therefore, endothelial Dll4
expression may be a closer surrogate marker of functional
tumor angiogenesis (providing a medium for progression
and metastasis) than microvessel density scores using
panendothelial markers. Independent validation of
these findings is imperative to confirm both the pattern
of Dll4 expression in breast adenocarcinomas and the
prognostic significance of endothelial Dll4 expression.
This is the first study to provide a comprehensive in situ
assessment of inflammatory markers in human breast
cancer. The data suggest that macrophages predomi-
nate in inflammatory infiltrates, with significant implica-
tions for angiogenesis in breast cancer, which has been
attributed, in part, to the secretion of proangiogenic fac-
tors by macrophages.56 Consistent with previously pub-
lished observations, expression of the myeloid cell
marker CD6857 was a weak adverse prognostic factor in
univariate analyses of overall survival, but not relapse-
free survival. Expression of DC-SIGN, an immature my-
eloid dendritic cell marker, was also a significant prog-
nostic factor in univariate analyses of overall survival, but
not relapse-free survival. However, few tissues ex-
pressed DC-SIGN (n  13), and the statistical signifi-
cance of these findings was not maintained in multivari-
ate analyses. Studies looking at markers of more mature
dendritic cells (CD1a and CD83)58,59 suggest that den-
dritic cell infiltration may be associated with a favorable
prognosis, but these markers are likely to detect different
dendritic cell subsets from the DC-SIGN positive popu-
lation.37 Moreover, the sample size for certain subset
analyses is n  200 (n  189 for neutrophil elastase, n 
192 for CD68, and n  151 for CA9) and analyses may,
therefore, be underpowered to detect a statistically sig-
nificant prognostic impact.
We have previously reported a statistically significant
adverse prognostic impact of CA9 in a series of 103
breast cancer whole sections with 6.2-year median fol-
low-up.60 This study failed to confirm CA9 as a statisti-
cally significant prognostic factor in overall survival or
relapse free survival in 151 breast cancers represented in
TMAs with 10-year median follow-up. The Kaplan-Meier
survival curves for CA9 showed it to be a significant
adverse prognostic factor in the first 8 years, but, by 16
years’ follow-up, this statistical significance was lost (data
not shown). Associations between CA9 and negative ER
status, and CA9 and high grade morphology were statis-
tically significant in both datasets.
In summary, Dll4 is expressed in cancer associated
endothelial cells, but not the endothelium adjacent to
nonlactating normal breast epithelium. This study sug-
gests that tumor endothelial expression of Dll4 is a sig-
nificant prognostic factor in early breast adenocarci-
noma. These data may have clinical relevance because
preclinical models28,29,61 suggest that assessing which
patients express Dll4 in their tumor endothelium may be
critical in predicting benefit from anti-VEGF therapies.
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